Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04624477|
Recruitment Status : Recruiting
First Posted : November 10, 2020
Last Update Posted : February 8, 2021
|Condition or disease|
|Papillary Thyroid Cancer Papillary Thyroid Carcinoma Papillary Microcarcinoma of the Thyroid|
This is a prospective, observational multi-center study, building on an initial single-centre study from Toronto, Canada (ClinicalTrials.gov Identifier: NCT03271892). Adult patients with small, low-risk papillary thyroid cancer may choose either active surveillance (close follow-up with the intention of surgery if the disease progresses or if the patient changes their mind and wants surgery) or immediate thyroid surgery (thyroidectomy). Patients who choose active surveillance are clinically followed at the participating study centre and those who choose surgery, receive usual care from their treating surgeon and/or other thyroid cancer specialists.
Thyroid cancer clinical and treatment outcomes are tracked (by medical record review) at least yearly for up to 10 years after enrollment. Patients are also asked to complete study questionnaires (patient reported outcomes) yearly for up to 5 years.
The underlying assumption in the study is that since patients' disease management goals differ for individuals choosing active surveillance and those choosing surgery, 'successful' disease management is defined differently for these patient groups. For patients choosing active surveillance, successful disease management may be defined by avoiding thyroid surgery for thyroid cancer progression (i.e. thyroid cancer that has grown or spread to other tissues). For patients choosing surgery, the ultimate goal is cure of the thyroid cancer (i.e. no thyroid cancer detected at long-term follow-up).
The primary analysis in this study is a description of how often patients' initial disease management goals are not achieved at long-term follow-up. For this study, 'failure' of disease management is defined as follows: a) in active surveillance group - surgery for disease progression, and b) in the immediate surgery group - requiring additional treatment for persistent or recurrent thyroid cancer (i.e. thyroid cancer that is detected and treated in follow-up). Thyroid cancer clinical and treatment outcomes as well as patient questionnaire outcomes will be reported.
|Study Type :||Observational|
|Estimated Enrollment :||450 participants|
|Official Title:||Active Surveillance or Surgery for Primary Management of Very Low Risk Papillary Thyroid Cancer: How Often Are the Long-term Disease Management Goals Achieved?|
|Actual Study Start Date :||February 3, 2021|
|Estimated Primary Completion Date :||March 31, 2025|
|Estimated Study Completion Date :||March 31, 2030|
Patients under active surveillance choose to not have immediate thyroid surgery. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if received). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
Immediate Thyroid Surgery (total or partial thyroidectomy)
Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
- Number of Participants in the Active Surveillance Group who Experience 'Failure' of Active Surveillance Disease Management [ Time Frame: Through study completion, an estimated average of 3 years ]'Failure' of Active Surveillance Disease Management is defined as: surgery for the indication of thyroid cancer that has progressed during study monitoring. Thyroid cancer disease progression under active surveillance includes: a) thyroid cancer enlargement > 3mm in largest dimension, b) thyroid cancer growth in a location that is concerning (e.g. extension outside of the thyroid, concerning proximity to critical structures such as the trachea or recurrent laryngeal nerve), or c) development of metastatic disease (in lymph nodes or distant organs). The specific type of disease progression will be reported.
- Number of Participants in the Surgical Group who Experience 'Failure' of Surgical Disease Management [ Time Frame: Through study completion, an estimated average of 3 years ]For patients who choose immediate surgery for management of thyroid cancer, the intent of surgery is curative. Thus, 'failure' of surgical disease management is defined by receiving additional treatment for structural thyroid cancer detected at follow-up (i.e. treatment of thyroid cancer detected on imaging or biopsy during follow-up). Additional thyroid cancer treatment may include additional surgery, radioactive iodine, ethanol ablation of lymph nodes, or external beam radiation treatment. The specific treatment used for recurrent or persistent thyroid cancer and the indication for the treatment will be reported.
- Number of Participants in Respective Thyroid Cancer Disease Status Categories at Last Follow-up [ Time Frame: Through study completion, an estimated average of 3 years ]The category of thyroid cancer disease status at last follow-up is recorded at least yearly. For patients in the active surveillance arm, disease status categories include: a) alive with no disease progression, b) alive with cross-over to surgery (with indication for surgery, including disease progression or other reason), c) death due to thyroid cancer, or d) death from any cause. For surgical patients and patients who crossed over to surgery from active surveillance, post-surgical disease status categories include: a) alive with no evidence of thyroid cancer structural disease at last follow-up (e.g.. no evidence of thyroid cancer on imaging or biopsy), b) alive with evidence of thyroid cancer structural disease present at last follow-up (i.e. evidence of thyroid cancer on imaging or biopsy), c) death due to thyroid cancer, or d) death from any cause.
- Number of Participants in the Active Surveillance Group who Undergo Thyroidectomy During Follow-up [ Time Frame: Through study completion, an estimated average of 3 years ]The number of participants in the active surveillance group who cross over to thyroidectomy during follow-up (with the specific indication for the thyroidectomy and type of thyroid surgery) will be reported.
- Number of Participants who Experience Long-term Complications of Thyroid Surgery [ Time Frame: Through study completion, an estimated average of 3 years ]For patients who undergo thyroidectomy during the study, the presence of long-term surgical complications (> 1 year after initial completion of surgery) will be reported. Specific surgical complications that will be tracked include: a) hypoparathyroidism (requiring prescription treatment), or b) recurrent laryngeal nerve injury.
- Description of Quality of Life (Thyroid Cancer-specific) [ Time Frame: Through study completion, an estimated average of 3 years ]EORTC QLQ-THY34 (all respective scales). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. All of the scales and single item measures range in score from 0 to 100. A high score for the symptom scales and single items indicates a worse outcome, whereas a high score for the Social Support scale represents a high level of functioning.
- Description of Quality of Life (Cancer-specific) [ Time Frame: Through study completion, an estimated average of 3 years ]EORTC QLQ-C30 (all respective scales). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high / healthy level of functioning (better outcome), a high score for the global health status /quality of life represents a better outcome, but a high score for a symptom scale / item represents a worse outcome.
- Measure of Anxiety [ Time Frame: Through study completion, an estimated average of 3 years ]Generalized Anxiety Disorder Screener questionnaire (minimum score 0, maximum score 21, where a higher score indicates a worse outcome)
- Measure of Survivor Concerns [ Time Frame: Through study completion, an estimated average of 3 years ]Assessment of Survivor Concerns questionnaire (Cancer Worry Subscale - minimum score 3, maximum score 12, where a higher score indicates a worse outcome and General Health Worry Subscale - minimum score 2, maximum score 8, where a higher score indicates a worse outcome)
- Measure of Decision Regret (relating to the original decision to undergo active surveillance or thyroid surgery). [ Time Frame: Through study completion, an estimated average of 3 years ]Decision Regret Scale (minimum score 0, maximum score 100, where a higher number indicates a worse outcome)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04624477
|Contact: Ogemdi Ihekire||416-340-4800 ext email@example.com|
|Contact: Anna Sawka||416-340-3678||Annie.Sawka@uhn.ca|
|Canada, Nova Scotia|
|Nova Scotia Health||Recruiting|
|Halifax, Nova Scotia, Canada, B3H1V8|
|Contact: Martin Corsten (902) 473-4420|
|Principal Investigator: Martin Corsten, MD|
|Lawson Health Research Institute||Recruiting|
|London, Ontario, Canada, N6C2R5|
|Contact: Halema Khan (519) 685-8500 ext 55398 firstname.lastname@example.org|
|Principal Investigator: Anthony Nichols, MD|
|Principal Investigator: Deric Morrison, MD|
|Ottawa Hospital Research Institute||Recruiting|
|Ottawa, Ontario, Canada, K1H 8L6|
|Contact: Stephanie Johnson-Obaseki|
|Contact (613) 798-5555 ext 78596|
|Principal Investigator: Stephanie Johnson-Obaseki, MD|
|University Health Network||Recruiting|
|Toronto, Ontario, Canada, M5G 2C4|
|Contact: Ogemdi Ihekire (416) 340-4800 ext 2601 email@example.com|
|Contact: Anna M Sawka, MD (416) 340-3678 Annie.Sawka@uhn.ca|
|Principal Investigator: David P Goldstein, MD, MSc|
|Principal Investigator: Anna M Sawka, MD, PhD|
|CHU de Québec - Université Laval||Recruiting|
|Québec, Quebec, Canada, G1V 4G2|
|Contact: Sarah Chouinard-Castonguay 418-654-2169 firstname.lastname@example.org|
|Principal Investigator: Maryse Brassard, MD|
|Principal Investigator: Nathalie Audet, MD|
|Principal Investigator:||Anna M Sawka, MD, PhD||University Health Network, Toronto|